{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:59:10Z","timestamp":1793930350997,"version":"4.8.0"},"reference-count":135,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Office of Scholarly Engagement - Harvard Medical School"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>\n                    Herpes zoster (HZ) is a neurocutaneous disease that causes significant morbidity worldwide. The disease is caused by the reactivation of the varicella-zoster virus (VZV), which leads to the development of a painful, vesicular rash and can cause complications such as post-herpetic neuralgia and vision loss. Globally, the incidence of HZ is increasing, and it incurs billions in cost annually to the healthcare system and to society through loss of productivity. With the advent of effective vaccines such as the live attenuated vaccine, Zostavax\n                    <jats:sup>\u00ae<\/jats:sup>\n                    , in 2006, and more recently the adjuvant recombinant subunit vaccine, Shingrix\n                    <jats:sup>\u00ae<\/jats:sup>\n                    , in 2017, HZ has become a preventable disease. However, access to the vaccines remains mostly limited to countries with developed economies, such as the United States and Canada. Even among countries with developed economies that license the vaccine, few have implemented HZ vaccination into their national immunization schedules due to cost-effectiveness considerations. In this review, we discuss the currently available HZ vaccines, landscape of HZ vaccine guidelines, and economic burden of disease in countries with developed and developing economies, as well as barriers and considerations in HZ vaccine access on a global scale.\n                  <\/jats:p>","DOI":"10.1177\/25151355221084535","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T07:58:11Z","timestamp":1647849491000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":96,"title":["Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4403-8508","authenticated-orcid":false,"given":"Catherina X.","family":"Pan","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, MA, USADepartment of Dermatology, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0188-3426","authenticated-orcid":false,"given":"Michelle S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA, USADepartment of Dermatology, Brigham and Women\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod E.","family":"Nambudiri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, 221 Longwood Avenue, Boston, MA 02115, USA Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"bibr1-25151355221084535","unstructured":"Herpes zoster vaccines SAGE Working Group on Varicella and Herpes Zoster Vaccines, https:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/april\/2_Background_document_Herpes_Zoster.pdf (2014, accessed 17 October 2021)."},{"key":"bibr2-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-016-0180-7"},{"key":"bibr3-25151355221084535","volume":"2019","author":"Gagliardi AMZ","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr4-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1177\/2051013615599151"},{"key":"bibr5-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001718"},{"key":"bibr6-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy418"},{"key":"bibr7-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2018.10.015"},{"key":"bibr8-25151355221084535","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23491"},{"key":"bibr9-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit405"},{"key":"bibr10-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1086\/430325"},{"key":"bibr11-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1302674"},{"key":"bibr12-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.11.013"},{"key":"bibr13-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0735-1"},{"key":"bibr14-25151355221084535","unstructured":"Shingles Zostavax Vaccination| What You Should Know| CDC, https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/public\/zostavax\/index.html (accessed 17 May 2021)."},{"key":"bibr15-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14683"},{"key":"bibr16-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu918"},{"key":"bibr17-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"bibr18-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603800"},{"key":"bibr19-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501184"},{"key":"bibr20-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1956906"},{"key":"bibr21-25151355221084535","unstructured":"GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over| GSK, https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-announces-approval-of-shingrix-in-china-for-prevention-of-shingles-in-adults-aged-50-and-over\/ (accessed 3 August 2021)."},{"key":"bibr22-25151355221084535","unstructured":"Annex 1: summary of product characteristics (Zostavax), https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zostavax-epar-product-information_en.pdf (2006, accessed 5 December 2021)."},{"key":"bibr23-25151355221084535","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-9-201005040-00004"},{"key":"bibr24-25151355221084535","unstructured":"GlaxoSmithKline Biologicals SA. Annex 1: summary of product characteristics (Shingrix), https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/shingrix-epar-product-information_en.pdf (2018, accessed 4 December 2021)."},{"key":"bibr25-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa083"},{"key":"bibr26-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir970"},{"key":"bibr27-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx245"},{"key":"bibr28-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.01.067"},{"key":"bibr29-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz359.183"},{"key":"bibr30-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30163-X"},{"key":"bibr31-25151355221084535","first-page":"181","volume":"70","author":"Vink P","year":"2020","journal-title":"Clin Infect Dis"},{"key":"bibr32-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31909"},{"key":"bibr33-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu606"},{"key":"bibr34-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa417.007"},{"key":"bibr35-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01076-w"},{"key":"bibr36-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.09.066"},{"key":"bibr37-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.07.005"},{"key":"bibr38-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.7431"},{"key":"bibr39-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab387"},{"key":"bibr40-25151355221084535","volume-title":"World Economic Outlook: Global Manufacturing Downturn, Rising Trade Barriers","year":"2019"},{"key":"bibr41-25151355221084535","unstructured":"Vaccine Scheduler| ECDC, https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=51&SelectedCountryIdByDisease=-1 (accessed 26 July 2021)."},{"key":"bibr42-25151355221084535","unstructured":"Ismail S, Tunis M, Baclic O, et al. Updated recommendations on the use of herpes zoster vaccines \u2013 Canada.ca, https:\/\/www.canada.ca\/en\/services\/health\/publications\/healthy-living\/updated-recommendations-use-herpes-zoster-vaccines.html (2018, accessed 26 July 2021)."},{"key":"bibr43-25151355221084535","doi-asserted-by":"publisher","DOI":"10.4161\/hv.4.3.5686"},{"key":"bibr44-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1262-8"},{"key":"bibr45-25151355221084535","first-page":"138","volume":"59","author":"Smetana J","year":"2010","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"bibr46-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.074"},{"key":"bibr47-25151355221084535","unstructured":"Mick SS, Lee S-YD, Wodchis WP. Variations in geographical distribution of foreign and domestically trained physicians in the United States: \u2018safety nets\u2019 or \u2018surplusor\u2019 surplus exacerbation\u2019? www.elsevier.com\/locate\/socscimed (accessed 30 July 2021)."},{"key":"bibr48-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-173"},{"key":"bibr49-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-012-0452-1"},{"key":"bibr50-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-12-136"},{"key":"bibr51-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-3153-y"},{"key":"bibr52-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1264834"},{"key":"bibr53-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-230"},{"key":"bibr54-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-11-33"},{"key":"bibr55-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01717-7"},{"key":"bibr56-25151355221084535","unstructured":"Van Lier E, De Melker H. Herpes zoster in the Netherlands background information for the Health Council, https:\/\/www.rivm.nl\/bibliotheek\/rapporten\/2018-0110.pdf (2018, accessed 23 September 2021)."},{"key":"bibr57-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-10-237"},{"key":"bibr58-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.11.054"},{"key":"bibr59-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.05.063"},{"key":"bibr60-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0951-7"},{"key":"bibr61-25151355221084535","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.7.15573"},{"key":"bibr62-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-012-0020-7"},{"key":"bibr63-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268808000678"},{"key":"bibr64-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125025"},{"key":"bibr65-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.11.012"},{"key":"bibr66-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021241"},{"key":"bibr67-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21599"},{"key":"bibr68-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-017-0119-4"},{"key":"bibr69-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2017.04.011"},{"key":"bibr70-25151355221084535","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2014.29.12.1706"},{"key":"bibr71-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2010.01.003"},{"key":"bibr72-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa014"},{"key":"bibr73-25151355221084535","unstructured":"Herpes zoster (shingles) vaccine: Canadian Immunization Guide \u2013 Canada.ca, https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-8-herpes-zoster-(shingles)-vaccine.html (accessed 27 July 2021)."},{"key":"bibr74-25151355221084535","unstructured":"Shingles vaccine good for seniors and health-care budgets| CBC| Radio, https:\/\/www.cbc.ca\/radio\/whitecoat\/shingles-vaccine-good-for-seniors-and-health-care-budgets-1.5259495 (accessed 28 July 2021)."},{"key":"bibr75-25151355221084535","unstructured":"What is the history of Shingles vaccine use in America? \u2013 NVIC, https:\/\/www.nvic.org\/vaccines-and-diseases\/shingles\/vaccine-history.aspx (accessed 26 July 2021)."},{"key":"bibr76-25151355221084535","first-page":"729","volume":"63","author":"Hales CM","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr77-25151355221084535","unstructured":"Zostavax| European Medicines Agency, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zostavax (accessed 27 July 2021)."},{"key":"bibr78-25151355221084535","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S176383"},{"key":"bibr79-25151355221084535","unstructured":"Commission implementing decision granting marketing authorisation under Regulation (EC) No 726\/2004 of the European Parliament and of the Council for \u2018Shingrix \u2013 herpes zoster vaccine (recombinant, adjuvanted)\u2019, a medicinal product for human use, https:\/\/ec.europa.eu\/health\/documents\/community-register\/2018\/20180321140171\/dec_140171_en.pdf (2018, accessed 27 July 2021)."},{"key":"bibr80-25151355221084535","unstructured":"EUnetHTA WP5 joint action 2 (2012-2015) Strand A, rapid relative effectiveness assessment of pharmaceuticals zostavax for the prevention of herpes zoster and postherpetic neuralgia pilot assessment using the draft HTA core model for rapid relative Effectiveness Assessment Pilot ID: WP-SA-1, https:\/\/www.eunethta.eu\/wp-content\/uploads\/2018\/01\/Zostavax-for-prevention-of-herpes-zoster-and-postherpetic-neuralgia_Rapid-REA_Final_Sep-2013_0.pdf"},{"key":"bibr81-25151355221084535","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010034"},{"key":"bibr82-25151355221084535","unstructured":"Sanofi Pasteur MSD\u2019s shingles vaccine now available in France, https:\/\/www.thepharmaletter.com\/article\/sanofi-pasteur-s-shingles-vaccine-now-available-in-france (accessed 27 July 2021)."},{"key":"bibr83-25151355221084535","unstructured":"Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute \u2013 2017\/2018, https:\/\/edoc.rki.de\/bitstream\/handle\/176904\/2878\/28CdDLdMqAkcg.pdf?sequence=1&isAllowed=y (2017, accessed 27 July 2021)."},{"key":"bibr84-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-019-02882-5"},{"key":"bibr85-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5459793"},{"key":"bibr86-25151355221084535","unstructured":"Immunization guidelines. Chapter 23: Varicella-Zoster. March 2020, https:\/\/www.hse.ie\/eng\/health\/immunisation\/hcpinfo\/guidelines\/chapter23.pdf"},{"key":"bibr87-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1657753"},{"key":"bibr88-25151355221084535","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1146726"},{"key":"bibr89-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.12.067"},{"key":"bibr90-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1581-4"},{"key":"bibr91-25151355221084535","unstructured":"Vaccine against Herpes zoster (Shingles), https:\/\/bindevevssykdommer.no\/en\/vaksiner\/vaksine-mot-herpes-zoster-helvetesild-shingels\/ (2020, accessed 5 December 2021)."},{"key":"bibr92-25151355221084535","unstructured":"Vaccination programmes \u2013 The Public Health Agency of Sweden, https:\/\/www.folkhalsomyndigheten.se\/the-public-health-agency-of-sweden\/communicable-disease-control\/vaccinations\/vaccination-programmes\/ (accessed 5 December 2021)."},{"key":"bibr93-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.06.008"},{"key":"bibr94-25151355221084535","unstructured":"Chickenpox \/ Shingles, https:\/\/www.bag.admin.ch\/bag\/en\/home\/krankheiten\/krankheiten-im-ueberblick\/windpocken.html (accessed 28 July 2021)."},{"key":"bibr95-25151355221084535","unstructured":"Rheuma Schweiz| von \u00c4rzten f\u00fcr \u00c4rzte: abstract 1800, https:\/\/www.rheuma-schweiz.ch\/index.php?id=1722 (accessed 12 October 2021)."},{"key":"bibr96-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.021"},{"key":"bibr97-25151355221084535","unstructured":"Shingles vaccine overview \u2013 NHS, https:\/\/www.nhs.uk\/conditions\/vaccinations\/shingles-vaccination\/ (accessed 22 July 2021)."},{"key":"bibr98-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025553"},{"key":"bibr99-25151355221084535","unstructured":"Vaccination against shingles Information for healthcare practitioners, https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1014037\/Shingles_HCP_guidance.pdf (2021, accessed 5 December 2021)."},{"key":"bibr100-25151355221084535","unstructured":"Statement on the clinical use of zoster vaccines in older adults in Australia, https:\/\/www.health.gov.au\/sites\/default\/files\/documents\/2021\/08\/statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia-statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia.pdf (2021, accessed 5 December 2021)."},{"key":"bibr101-25151355221084535","unstructured":"Goods Administration T. Australian public assessment report for recombinant varicella zoster virus (VZV) glycoprotein E (gE) antigen about the therapeutic goods administration (TGA), https:\/\/www.tga.gov.au (2018, accessed 12 October 2021)."},{"key":"bibr102-25151355221084535","unstructured":"Zoster vaccines for Australian adults, https:\/\/www.ncirs.org.au\/sites\/default\/files\/2018-12\/zoster-vaccine-fact-sheet.pdf (2017, accessed 12 October 2021)."},{"key":"bibr103-25151355221084535","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"bibr104-25151355221084535","unstructured":"23. Zoster (herpes zoster\/shingles) \u2013 Immunisation Handbook 2020| Ministry of Health NZ, https:\/\/www.health.govt.nz\/our-work\/immunisation-handbook-2020\/23-zoster-herpes-zoster-shingles (accessed 4 August 2021)."},{"key":"bibr105-25151355221084535","doi-asserted-by":"publisher","DOI":"10.11150\/kansenshogakuzasshi.85.161"},{"key":"bibr106-25151355221084535","unstructured":"Shingrix approved in Europe and Japan, https:\/\/www.thepharmaletter.com\/article\/shingrix-approved-in-europe-and-japan (accessed 12 October 2021)."},{"key":"bibr107-25151355221084535","doi-asserted-by":"publisher","DOI":"10.17265\/2159-5313\/2016.09.003"},{"key":"bibr108-25151355221084535","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2015.47.1.68"},{"key":"bibr109-25151355221084535","unstructured":"SK Chemicals\u2019 shingles vaccine wins regulatory approval in Korea, http:\/\/www.koreaherald.com\/view.php?ud=20171009000224 (accessed 4 August 2021)."},{"key":"bibr110-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268811001786"},{"key":"bibr111-25151355221084535","doi-asserted-by":"crossref","first-page":"e0152660","DOI":"10.1371\/journal.pone.0152660","volume":"11","author":"Li Y","year":"2016","journal-title":"PLoS ONE"},{"key":"bibr112-25151355221084535","unstructured":"MSGM \u2013 the herpes zoster vaccine, https:\/\/sites.google.com\/a\/ummc.edu.my\/msgm\/position-statements\/the-herpes-zoster-vaccine (accessed 18 October 2021)."},{"key":"bibr113-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2198-y"},{"key":"bibr114-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04715.x"},{"key":"bibr115-25151355221084535","first-page":"693","volume":"69","author":"Albrecht P","year":"2015","journal-title":"Przegl Epidemiol"},{"key":"bibr116-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255877"},{"key":"bibr117-25151355221084535","first-page":"125","volume":"68","author":"Vujacich C","year":"2008","journal-title":"Medicina (B Aires)"},{"key":"bibr118-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833"},{"key":"bibr119-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.02.021"},{"key":"bibr120-25151355221084535","doi-asserted-by":"publisher","DOI":"10.5339\/qmj.2020.1"},{"key":"bibr121-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1792290"},{"key":"bibr122-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1184801"},{"key":"bibr123-25151355221084535","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28670"},{"key":"bibr124-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1509645"},{"key":"bibr125-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-019-00491-6"},{"key":"bibr126-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1177\/003591576505800106"},{"key":"bibr127-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1094-7"},{"key":"bibr128-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1538801"},{"key":"bibr129-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/S1576-9887(11)70012-7"},{"key":"bibr130-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-019-01423-z"},{"key":"bibr131-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.040"},{"key":"bibr132-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011539"},{"key":"bibr133-25151355221084535","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220230"},{"key":"bibr134-25151355221084535","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2013.01.120154"},{"key":"bibr135-25151355221084535","doi-asserted-by":"publisher","DOI":"10.5070\/D39N03W07G"}],"container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25151355221084535","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/25151355221084535","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/25151355221084535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T05:02:24Z","timestamp":1740891744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/25151355221084535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":135,"alternative-id":["10.1177\/25151355221084535"],"URL":"https:\/\/doi.org\/10.1177\/25151355221084535","relation":{},"ISSN":["2515-1355","2515-1363"],"issn-type":[{"value":"2515-1355","type":"print"},{"value":"2515-1363","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"25151355221084535"}}